PAP
REGN icon

Persistent Asset Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Persistent Asset Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-46
Closed -$112K – 226
2025
Q1 		$112K Buy
+46
New +$31.6K 0.09% 115

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Persistent Asset Partners's REGN Position: Q2 2026 in Review

Persistent Asset Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 400 shares — an estimated $309K sold.

Persistent Asset Partners first reported a position in REGN in Q1 2025 and held it in 5 quarters. The position peaked at $4.43M in Q1 2025. 1,335 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Persistent Asset Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 400 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $309K.
  • Persistent Asset Partners first reported a position in Regeneron Pharmaceuticals in Q1 2025 and held it in 5 quarters.
  • Persistent Asset Partners's Regeneron Pharmaceuticals position peaked at $4.43M in Q1 2025.
  • 1,335 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.